Global private equity firms flock to China-based I-Mab

I-Mab Biopharma announced a $418 million private placement deal, with numerous private equity managers joining Hillhouse Capital in supporting the biologics company.

In addition to Hillhouse, which led the financing round, Singapore’s GIC joined other leading Asian and U.S. biotech investment funds, including OrbiMed, Octagon Capital Advisors, Perceptive Advisors, Cormorant Asset Management, Sphera Healthcare and Alyeska Investment Group.

I-Mab sold over 29 million ordinary shares in the deal as the company said it is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.